Fairvalue-Calculator Fairvalue-Calculator
EN DE

PTC Therapeutics, Inc (PTCT) Fair Value & Analysis

Healthcare · US · Market cap $5.7B

Price$84.41
Fair Value$157.05
Upside+86.1%
Quality95/100
Evidence: High Range $119.27 – $195.86

Fair value as of: Jun 25, 2026

Analysis

PTC Therapeutics, Inc (PTCT) currently trades at $84.41, while our model-based Fair Value estimate is $157.05 — implying the stock looks roughly 86.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundatio…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is PTC Therapeutics, Inc (PTCT) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $157.05 versus a price of $84.41 — about +86% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PTCT?
Our 21-model fair value for PTC Therapeutics, Inc is $157.05 (as of Jun 25, 2026), built from audited fundamentals. The current price is $84.41.
What is the quality score of PTCT?
PTC Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.